Biocon Biologics presents dermatology data at EADV 2024 Congress, showcasing interchangeability and biosimilarity of ...

Switching between adalimumab and adalimumab-fkjp in Phase 3 study in patients with chronic plaque psoriasis supports ...

New clinical data on Almirall’s biologics portfolio demonstrates further opportunities to positively impact patients and the ...

Access to adequate care for psoriasis is inconsistent across Europe and the condition remains misunderstood and undertreated.

In October 2023, bimekizumab was approved for moderate to severe plaque psoriasis in adults who are eligible for systemic therapy or phototherapy. 6 With the new indications, bimekizumab is the first ...

The global psoriasis therapeutics market revenue was around US$ 25.0 billion in 2022 and is estimated to reach US$ 55.8 billion by 2031, growing at a compound annual growth rate (CAGR) of 9.3% during ...

Flakes won’t go away? You might be dealing with scalp psoriasis instead of dandruff! Here's how to know the difference ...

Psoriasis itself doesn't make you immunocompromised, however, medications that treat the condition can suppress the immune ...

The three new nods stand to bolster the company’s stated peak sales expectations ... Despite the hold-up, Bimzelx’s launch in ...

Expected sometime in 2025, details on plans for enrollment by race, ethnicity, age, and sex will be required for all pivotal ...

Switching between adalimumab and adalimumab-fkjp in Phase 3 study in patients with chronic plaque psoriasis supports interchangeability between adalimumab and adalimumab-fkjpBiosimilarity between ...

Prurigo nodularis is a chronic, itchy skin condition that causes firm and painful bumps and raised patches. Medications and ...